Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Bananas are packed with vitamins and minerals, but are they wise to eat on a weight loss drug? We turned to the experts to find out the best way to incorporate this fruit into your diet while you’re ...

GLP-1 agonist medications ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum of 15 mg per week, based ...

预计到 2025 年，全球肥胖人数将达到 15.5 亿人，到 2030 年更是会涨到 19.9 亿人，这段时间的复合年增长率都是 ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Data on the type of GLP-1 analogue (subcutaneous semaglutide and liraglutide), the initial start ... Most patients (86%) were prescribed subcutaneous semaglutide, and 14% were prescribed liraglutide.